News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MT Newswires Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after โฆ
Cullinan Therapeutics (Nasdaq: CGEM) has announced key fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline. The company plans to release multi-dose regimen data for CLN-978 in SLE, RA, and Sjรถgren's disease in December, and for Velinotamig in SLE at โฆ
Cullinan Therapeutics (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1:30 โฆ
BTIG has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $40 from $39, maintaining a Buy rating, following positive Phase 3 trial results for its drug zipalertinib. The drug, in combination with chemotherapy, reduced disease progression risk by 50% in certain lung cancer โฆ
TD Cowen has reaffirmed its Buy rating on Cullinan Oncology Inc. (NASDAQ:CGEM), projecting peak sales of $225 million for its drug, with potential upside to $1 billion due to promising REZILIENT3 trial results. The company recently announced positive Phase 3 trial results for zipalertinib โฆ
Stifel reiterated a Buy rating and $28.00 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) after positive Phase 3 trial data for its cancer drug candidate, Zipalertinib, which showed a significant progression-free survival benefit. The stock has seen substantial gains, with InvestingPro analysis noting that โฆ
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive results from their Phase 3 REZILIENT3 trial. The trial evaluated zipalertinib plus chemotherapy for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, showing a statistically significant and clinically meaningful improvement โฆ
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive results from their Phase 3 REZILIENT3 trial. The trial evaluated zipalertinib plus chemotherapy for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, showing a statistically significant and clinically meaningful improvement โฆ
Cullinan Therapeutics will host a virtual event on September 14, 2026, to discuss the interim analysis results of its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy. The trial, focusing on first-line EGFR exon 20 insertion mutation-positive NSCLC, met its primary endpoint of progression-free โฆ
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near-term sentiment despite long-term strength, according to AI models. The analysis highlights a mid-channel oscillation pattern and presents three distinct trading strategies: a long position trading strategy, a breakout strategy, and a short risk hedging strategy, โฆ
Cullinan Oncology stock recently hit a 52-week high of $23.07, demonstrating a 200% increase over the past year and a 122% year-to-date return, with a market capitalization of $1.48 billion. Despite this strong performance, InvestingPro suggests the stock may be overvalued relative to its โฆ
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which studied zipalertinib for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell โฆ
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive Phase 3 results for zipalertinib plus chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The REZILIENT3 trial met its primary endpoint of improved progression-free survival, positioning zipalertinib as a โฆ
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that data from their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) has been selected for presentation at the IASLC 2026 World Conference on โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States